Categories AlphaGraphs, Consumer, Earnings

Earnings: A snapshot of Lennar’s (LEN) Q2 2022 financial results

Lennar Corporation (NYSE: LEN) on Tuesday announced second-quarter 2022 financial results, reporting higher revenues and earnings. The results also exceeded consensus estimates.

Net income attributable to the company was $1.32 billion or $4.49 per share in the second quarter, compared to $831.4 million or $2.65 per share last year. Excluding special items, earnings increased to $4.69 per share from $2.95 per share in the prior-year period.

Revenues increased 30% year-over-year to $8.4 billion during the three-month period, and deliveries rose 14% to 16,549 homes. Analysts were looking for slower top-line growth.

Read management/analysts’ comments on quarterly results

“During the quarter, our homebuilding machine continued to be intensely focused on production. Our cycle time during the quarter increased only slightly sequentially so it appears that the well-documented supply chain issues have started to subside. Our quarterly starts and sales pace remained strong at 6.2 homes and 5.0 homes per community, respectively, in the second quarter,” said Jon Jaffe, co-chief executive officer of Lennar.

Prior Performance

  • Lennar Corporation Q1 2022 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Key takeaways from JM Smucker’s (SJM) Q2 2024 earnings report

Shares of the J.M. Smucker Co. (NYSE: SJM) were up over 4% on Tuesday after the company reported its earnings results for the second quarter of 2024. Profits beat expectations

Nio reports Q3 2023 results. Here’s all you need to know

Electric car maker NIO Inc. (NYSE: NIO) reported a net loss for the third quarter of 2023, despite a sharp increase in revenues. The China-based company also provided its guidance

Ocean Biomedical’s breast cancer research uncovers new tumor suppression pathway for its proprietary antibody

Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said that new findings, co-authored by the company’s scientific co-founder Jack A. Elias in the peer-reviewed journal Immunity, have revealed the

Add Comment
Viewing Highlight